Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Wilhelm

Podiatrist, Foot Surgery Centreville, VA Doctor of Podiatric Medicine

NPI 1841287414 CMS profile 83896

6101 Redwood Square Ctr, Suite 303, Centreville, VA 20121

Open in the dashboard

General payments

$8,153

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Wilhelm of Centreville, VA is reported in the CMS Open Payments database as having received $8,153 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $456 11
2024 General $547 11
2023 General $404 10
2022 General $1,454 14
2021 General $514 19
2020 General $286 9
2019 General $4,491 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Wilhelm
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Kenneth Wilhelm were reported at $456. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Kenneth Wilhelm Podiatrist, Foot Surgery median Middle half National median
2019 $4,491 $167 $67–$484 $163
2020 $286 $114 $40–$323 $114
2021 $514 $171 $57–$502 $132
2022 $1,454 $196 $66–$556 $149
2023 $404 $187 $78–$466 $160
2024 $547 $190 $78–$557 $164
2025 $456 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $3,559 15 payments
  2. Supreme Orthopedic Systems, LLC $1,792 7 payments
  3. Integra LifeSciences Corporation $296 2 payments
  4. Horizon Therapeutics plc $292 21 payments
  5. Medtronic, Inc. $233 7 payments
  6. Cardiovascular Systems Inc. $216 2 payments
  7. Paratek Pharmaceuticals, Inc. $182 5 payments
  8. Merck Sharp & Dohme Corporation $159 4 payments
  9. Smith+Nephew, Inc. $148 2 payments
  10. ConvaTec Inc. $125 1 payment
  11. Other $1,152 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $4,568 5 payments
  2. Food and Beverage $3,030 99 payments
  3. Travel and Lodging $556 3 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $217 6 payments
  2. Diamondback Peripheral $216 2 payments
  3. NUZYRA $182 5 payments
  4. SIVEXTRO $159 4 payments
  5. Integra Recon-Skin And Wound $155 1 payment
  6. Integra Recon-Skin And Wound $155 1 payment
  7. PRIMATRIX $155 1 payment
  8. Integra Recon-Skin And Wound $155 1 payment
  9. INTEGRA DERMAL REGENERATION TEMPLATE $155 1 payment
  10. AMNIOEXCEL $141 1 payment
  11. Other $3,118 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

534

Median for Podiatry: 160

Drug cost

$10,327

Median for Podiatry: $2,368

Branded share of claims

9.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 225 $5,667
Ciclopirox Generic 23 $2,350
Diclofenac Sodium Generic 53 $600
Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort Brand 14 $559
Meloxicam Generic 104 $250
Gabapentin Generic 29 $208
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $195
Mupirocin Generic 22 $187
Terbinafine Hcl Generic 12 $143
Methylprednisolone Generic 15 $133

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$140,395

Of which drugs: $70

Medicare patients

484

Average age 76

Services billed

2,911

297 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 33%
Ischemic heart disease 25%
Chronic kidney disease 23%
Atrial fibrillation 19%
Cancer 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 47 695 $59

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $150
$150 — —
KRYSTEXXA
  • Amgen Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record